Latest News & Features
Americas
Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has brought another two patent challenges against Gilead over its hepatitis C medicine sofosbuvir. 8 December 2017
Big Pharma
An advocate general has said that regulatory authorities in “concerned” EU member states handling drug marketing authorisations are co-responsible for approved documents on data exclusivity. 7 December 2017
Americas
An IBM counsel has discussed how companies can harness their IP and gave an overview of the impact of artificial intelligence on healthcare. 7 December 2017
Big Pharma
An end of procedure notice issued by a reference EU member state before the expiry of a basic patent may not be treated as equivalent to a marketing authorisation. 7 December 2017
Europe
Brexit and second medical use patent claims were two topics featured in the roundtable discussions at Life Sciences Patent Network Europe, a conference held in London. 7 December 2017
Biotechnology
Attendees at yesterday’s Life Sciences Patent Network Europe conference learned exactly what in-house counsel want when it comes to private practice lawyers. 7 December 2017
Asia-Pacific
Basilea Pharmaceutica and Pfizer have reached a deal for a licence agreement for the antifungal medication Cresemba to cover China and 16 countries in the Asia-Pacific region. 7 December 2017
Americas
One of the key players in the CRISPR landscape initially had “no clue” about licensing the technology in the agricultural sector. 7 December 2017
Biotechnology
Avoid using the colour blue and slogans when attempting to register a trademark for a pharmaceutical product at the European Union Intellectual Property Office , one lawyer has advised. 6 December 2017
Big Pharma
The UK Supreme Court’s approach in Actavis v Eli Lilly brought the country closer to harmonisation with other European nations, but there’s still not a wholly consistent view on the doctrine of equivalents across Europe. 6 December 2017